209 related articles for article (PubMed ID: 21596659)
1. Therapeutic interventions targeting organ preservation in muscle-invasive bladder cancer: a review.
Koukourakis G; Kouloulias V; Zacharias G; Sotiropoulou-Lontou A; Koukourakis M
Clin Transl Oncol; 2011 May; 13(5):315-21. PubMed ID: 21596659
[TBL] [Abstract][Full Text] [Related]
2. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
Khosravi-Shahi P; Cabezón-Gutiérrez L
Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598
[TBL] [Abstract][Full Text] [Related]
3. Bladder preservation protocols in the treatment of muscle-invasive bladder cancer.
Torres-Roca JF
Cancer Control; 2004; 11(6):358-63. PubMed ID: 15625523
[TBL] [Abstract][Full Text] [Related]
4. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.
Smith ZL; Christodouleas JP; Keefe SM; Malkowicz SB; Guzzo TJ
BJU Int; 2013 Jul; 112(1):13-25. PubMed ID: 23356411
[TBL] [Abstract][Full Text] [Related]
5. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.
Mitin T; Shipley WU; Efstathiou JA; Heney NM; Kaufman DS; Lee RJ; Zietman AL
Curr Urol Rep; 2013 Apr; 14(2):109-15. PubMed ID: 23341373
[TBL] [Abstract][Full Text] [Related]
6. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
[TBL] [Abstract][Full Text] [Related]
7. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Johnson SB; Yu JB
Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
[TBL] [Abstract][Full Text] [Related]
8. [Radiochemotherapy for invasive bladder cancer : An update].
Tselis N; Prott FJ; Ott O; Weiss C; Rödel C
Urologe A; 2018 Jun; 57(6):679-685. PubMed ID: 29651707
[TBL] [Abstract][Full Text] [Related]
9. Can bladder preservation therapy come to the center stage?
Inamoto T; Ibuki N; Komura K; Juri H; Yamamoto K; Yamamoto K; Fujita K; Nonomura N; Narumi Y; Azuma H
Int J Urol; 2018 Feb; 25(2):134-140. PubMed ID: 29171098
[TBL] [Abstract][Full Text] [Related]
10. A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.
Cao C; Fu Z; Liu Y; Zhou A; Wang J; Shou J
Front Immunol; 2021; 12():684879. PubMed ID: 34177933
[TBL] [Abstract][Full Text] [Related]
11. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
12. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy.
Zietman AL; Shipley WU; Kaufman DS
Ann Med; 2000 Feb; 32(1):34-42. PubMed ID: 10711576
[TBL] [Abstract][Full Text] [Related]
13. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
[TBL] [Abstract][Full Text] [Related]
14. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
Gamal El-Deen HS
J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
[TBL] [Abstract][Full Text] [Related]
15. Bladder sparing surgery in high-grade bladder cancer.
Yakovlev PG; Klyushin DA; Vereshchako RI
Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
[TBL] [Abstract][Full Text] [Related]
16. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma.
Aboziada MA; Hamza HM; Abdlrahem AM
J Egypt Natl Canc Inst; 2009 Jun; 21(2):167-74. PubMed ID: 21057568
[TBL] [Abstract][Full Text] [Related]
17. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.
Shipley WU; Kaufman DS; Zehr E; Heney NM; Lane SC; Thakral HK; Althausen AF; Zietman AL
Urology; 2002 Jul; 60(1):62-7; discussion 67-8. PubMed ID: 12100923
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?
Kuczyk M; Turkeri L; Hammerer P; Ravery V;
Eur Urol; 2003 Jul; 44(1):57-64. PubMed ID: 12814676
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]